Welcome to our dedicated page for Endra Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on Endra Life Sciences stock.
ENDRA Life Sciences Inc (NDRA) pioneers advanced medical imaging through its TAEUS technology and Nexus 128 system, offering non-invasive solutions for liver diagnostics and preclinical research. This page consolidates all official announcements and third-party analyses about the company’s technological advancements and strategic initiatives.
Access real-time updates on regulatory milestones, clinical trial progress, and partnerships driving innovation in photoacoustic imaging. Investors and researchers will find detailed coverage of product developments like the TAEUS liver fat quantification system and Nexus 128’s 4D scanning capabilities.
Key updates include financial results, intellectual property filings, and collaborations with global research institutions. All content is verified for accuracy and relevance to ensure informed decision-making about this emerging leader in cost-effective diagnostic imaging.
Bookmark this page to stay informed about NDRA’s progress in addressing unmet needs in NAFLD/NASH diagnosis and expanding applications of thermo-acoustic ultrasound technology across healthcare markets.
ENDRA Life Sciences (NASDAQ:NDRA) has been granted Chinese Patent ZL 2018 8 00500526 for its Thermo Acoustic Enhanced UltraSound (TAEUS) technology. This patent, the eighth for ENDRA in China, enhances its intellectual property portfolio, now totaling 78 assets. TAEUS provides a non-invasive method to assess liver fat, crucial for the estimated 30% of China's population suffering from Non-Alcoholic Fatty Liver Disease (NAFLD). The technology offers a cost-effective alternative to MRIs and biopsies, utilizing existing ultrasound systems for patient care.
ENDRA Life Sciences (NASDAQ: NDRA) has renewed its collaboration agreement with GE Healthcare, extending the partnership until December 16, 2023. This agreement will support the commercialization of ENDRA's TAEUS technology for imaging Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). Recent advancements include deployment of TAEUS systems at Rocky Vista University and UPMC, a clinical evaluation agreement in France, and an exclusive distribution deal in Vietnam for over 40 systems. ENDRA aims to enhance ultrasound capabilities and address critical clinical needs in liver assessments.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) has completed its public offering of 7,857,286 shares of common stock at $0.70 per share, raising $5,500,100 before expenses. The underwriter, ThinkEquity, exercised its over-allotment option for an additional 714,286 shares. The offering was made under an effective shelf registration statement filed with the SEC. ENDRA focuses on developing its TAEUS technology for improved tissue visualization, particularly for liver conditions affecting over 1 billion people globally, which currently lack practical diagnostic tools.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) has announced a public offering of 7,143,000 shares of common stock priced at $0.70 per share, aiming to raise approximately $5.0 million before expenses. The underwriter has a 45-day option to purchase an additional 714,286 shares to cover over-allotments, potentially increasing gross proceeds to $5.5 million. The offering is slated to close on December 18, 2020. Funds will be allocated for working capital and general corporate purposes.
ENDRA Life Sciences (NASDAQ:NDRA) announced a proposed underwritten public offering of common stock. The company plans to grant the underwriter a 45-day option to purchase additional shares. The offering is subject to market conditions, with no guarantee on its completion or terms. ENDRA intends to utilize the net proceeds for working capital and general corporate purposes. ThinkEquity is acting as the sole underwriter. A shelf registration statement has been filed with the SEC, and preliminary prospectus materials will also be available.
ENDRA Life Sciences (NASDAQ:NDRA) has received its seventh Chinese patent for TAEUS technology, aimed at addressing clinical needs like Non-Alcoholic Fatty Liver Disease. The new patent, ZL 2016 8 00267062, enhances ENDRA’s intellectual property protection in China, where approximately 30% of the population is affected by liver disease. The company’s patent portfolio now includes 78 assets, with further developments expected in the US and Europe. This patent supports ENDRA’s goal of optimizing hybrid ultrasound and thermoacoustic imaging for various clinical applications.
ENDRA Life Sciences (NASDAQ: NDRA) has signed an exclusive distribution agreement with Quang Phat Technology Science Equipment Co. Ltd. to sell at least 40 TAEUS liver imaging systems in Vietnam. The agreement, effective over three years, hinges on securing FDA clearance and local approvals before sales commence. This marks ENDRA's first commercial agreement in Southeast Asia, aimed at addressing the rising incidence of NAFLD in Vietnam's 96 million population. ENDRA aims to capitalize on its innovative technology to provide non-invasive liver disease diagnostics.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) has partnered with Centre Hospitalier Universitaire d'Angers, France, to conduct a clinical study on its Thermo Acoustic Enhanced Ultrasound (TAEUS) device for assessing Non-Alcoholic Fatty Liver Disease (NAFLD). This study aims to compare TAEUS with standard MRI measures, targeting 75 patients to enhance clinical evidence and support TAEUS commercialization in Europe. NAFLD, affecting over 1 billion globally, poses significant healthcare challenges.
ENDRA Life Sciences (NASDAQ:NDRA) announced that Rocky Vista University College of Osteopathic Medicine has initiated patient scans using its TAEUS system to evaluate Non-Alcoholic Fatty Liver Disease (NAFLD) in Utah. This marks the first real-world use of TAEUS in the U.S. The study aims to analyze 200 volunteers while collecting clinical data to bolster commercialization efforts. ENDRA has received the CE mark for European sales and is seeking FDA clearance in the U.S. The initiative highlights TAEUS's potential in addressing a significant clinical need for non-invasive liver assessments.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) will present at the virtual Fall Investor Summit from November 16th-18th. The summit will feature 75 companies and over 300 investors, connecting smallcap and microcap firms with qualified investors.
ENDRA is known for its innovative Thermo-Acoustic Enhanced UltraSound (TAEUS) technology, which aims to revolutionize ultrasound by enabling visualization of tissue composition and function. This technology will initially focus on assessing fat in the liver for early detection of Non-Alcoholic Fatty Liver Disease (NAFLD-NASH).
